Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. UNCY
stocks logo

UNCY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.472
-81.86%
--
--
0.378
-175.6%
--
--
1.162
-323.46%
Estimates Revision
The market is revising Downward the revenue expectations for Unicycive Therapeutics, Inc. (UNCY) for FY2025, with the revenue forecasts being adjusted by -25% over the past three months. During the same period, the stock price has changed by 49.08%.
Revenue Estimates for FY2025
Revise Downward
down Image
-25%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-40.73%
In Past 3 Month
Stock Price
Go Up
up Image
+49.08%
In Past 3 Month
Wall Street analysts forecast UNCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UNCY is 36.60 USD with a low forecast of 21.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast UNCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UNCY is 36.60 USD with a low forecast of 21.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.500
sliders
Low
21.00
Averages
36.60
High
60.00
Current: 6.500
sliders
Low
21.00
Averages
36.60
High
60.00
H.C. Wainwright
H.C. Wainwright
NULL -> Buy
maintain
$9 -> $22
2025-10-29
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$9 -> $22
2025-10-29
maintain
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Unicycive Therapeutics to $22 from $9 and keeps a Buy rating on the shares. The believes the company's regulatory overhang has been revolved after its Type A meeting with the FDA. Unicycive plans to file a response to the complete response letter by year-end and expects a decision in the first half of 2026, the analyst tells investors in a research note.
Benchmark
Speculative Buy
maintain
$3 -> $21
2025-09-15
Reason
Benchmark
Price Target
$3 -> $21
2025-09-15
maintain
Speculative Buy
Reason
Benchmark raised the firm's price target on Unicycive Therapeutics to $21 from $3 and keeps a Speculative Buy rating on the shares, noting that the firm's new price target reflects a 1:10 reverse split and an updated discount rate after Unicycive said that it plans to complete a Type A meeting with the FDA to gain alignment on the best strategy to resolve the remaining issues outlined in the complete response letter for the oxylanthanum carbonate New Drug Application.
Lucid Capital
Elemer Piros
Buy
initiated
$12
2025-06-04
Reason
Lucid Capital
Elemer Piros
Price Target
$12
2025-06-04
initiated
Buy
Reason
H.C. Wainwright
Buy
initiated
$9
2025-05-27
Reason
H.C. Wainwright
Price Target
$9
2025-05-27
initiated
Buy
Reason
H.C. Wainwright assumed coverage of Unicycive Therapeutics with a Buy rating and $9 price target. Unicycive is a clinical stage biotechnology company developing novel therapies for treating kidney diseases, the analyst tells investors in a research note. The firm expects a positive decision by the FDA for the company's leading clinical candidate, oxylanthanum carbonate, for lowering high phosphate levels or hyperphosphatemia in chronic kidney disease patients undergoing dialysis and expects management to launch the drug by the end of 2025.
Guggenheim
Vamil Divan
Strong Buy
Initiates
$6
2025-04-21
Reason
Guggenheim
Vamil Divan
Price Target
$6
2025-04-21
Initiates
Strong Buy
Reason
Guggenheim initiated coverage of Unicycive Therapeutics with a Buy rating and $6 price target.
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$7.5
2025-04-11
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$7.5
2025-04-11
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Unicycive Therapeutics Inc (UNCY.O) is 1.78, compared to its 5-year average forward P/E of -0.50. For a more detailed relative valuation and DCF analysis to assess Unicycive Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.50
Current PE
1.78
Overvalued PE
6.57
Undervalued PE
-7.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6159.69
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
22561.10
Undervalued EV/EBITDA
-34880.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.48
Current PS
0.00
Overvalued PS
16.69
Undervalued PS
-7.73
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

UNCY News & Events

Events Timeline

(ET)
2025-11-12
07:17:21
Unicycive Therapeutics projects funding to last until 2027
select
2025-11-12
07:17:04
Unicycive Therapeutics Announces Q3 EPS of 46c, Below Consensus Estimate of 53c
select
2025-10-30 (ET)
2025-10-30
07:19:23
Unicycive Therapeutics to Showcase New OLC Findings at ASN Kidney Week 2025
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
12-03Globenewswire
Five Below (FIVE) Class Action Survives Dismissal Motion Amid Securities Fraud Allegations
  • Lawsuit Survival: Five Below's shareholder class action survives a motion to dismiss, as the court found that plaintiffs plausibly allege misleading information regarding the company's financial health and operations, potentially leading to corporate reforms and fund recovery.
  • Financial Transparency Issues: The lawsuit alleges that executives failed to disclose serious issues related to inventory management and market trends, which not only undermines investor confidence but could also lead to future performance declines.
  • Shareholder Rights Protection: Shareholders holding Five Below stock can seek court-approved incentive awards at no cost, a move that may encourage more shareholders to participate in the lawsuit, increasing pressure on corporate governance.
  • Potential Market Impact: As the lawsuit progresses, Five Below may face greater market pressure, with investor confidence in its future financial performance likely to wane, potentially affecting stock price performance.
[object Object]
Preview
7.0
12-03Globenewswire
Cytokinetics Faces Shareholder Investigation Over Alleged Misstatements
  • Shareholder Investigation Initiated: Grabar Law Office is investigating whether Cytokinetics' executives breached their fiduciary duties, allowing shareholders to seek corporate reforms and fund recovery, highlighting potential governance risks within the company.
  • FDA Review Delay: On May 1, 2025, Cytokinetics announced that the FDA extended the review date for aficamten's NDA from September 26, 2025, to December 26, 2025, indicating compliance issues that could undermine future market confidence.
  • Impact of Misstatements: Company executives acknowledged that they submitted the NDA without including a Risk Evaluation and Mitigation Strategy (REMS), leading to misleading statements about the company's prospects, which could result in significant financial harm to shareholders.
  • Potential Legal Consequences: These misleading statements may expose Cytokinetics to lawsuits and liability, further impacting its stock price and market reputation, underscoring deficiencies in the company's transparency and compliance practices.
[object Object]
Preview
2.0
12-02NASDAQ.COM
Post-Market Highlights: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, and Protara See Gains After Trading Hours

  • Biotech Gains in After-Hours Trading: Several biotechnology and pharmaceutical companies saw significant stock price increases in after-hours trading, driven by corporate updates and upcoming events.

  • Jasper Therapeutics' Webinar Announcement: Jasper Therapeutics, Inc. experienced a 21.51% surge after announcing a webinar to discuss findings from the BEACON study and preliminary data from the ETESIAN study.

  • NRx Pharmaceuticals' Presentation at NobleCon21: NRx Pharmaceuticals, Inc. rose 13.39% following the announcement that its CEO will present updates on the company's focus and clinical revenue at an upcoming conference.

  • Protara Therapeutics' Conference Call: Protara Therapeutics, Inc. gained 5.04% after revealing plans for a conference call to discuss interim data from its Phase 2 trial for bladder cancer, with findings to be presented at a major urology meeting.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Unicycive Therapeutics Inc (UNCY) stock price today?

The current price of UNCY is 6.5 USD — it has increased 5.35 % in the last trading day.

arrow icon

What is Unicycive Therapeutics Inc (UNCY)'s business?

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

arrow icon

What is the price predicton of UNCY Stock?

Wall Street analysts forecast UNCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UNCY is 36.60 USD with a low forecast of 21.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Unicycive Therapeutics Inc (UNCY)'s revenue for the last quarter?

Unicycive Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Unicycive Therapeutics Inc (UNCY)'s earnings per share (EPS) for the last quarter?

Unicycive Therapeutics Inc. EPS for the last quarter amounts to -0.33 USD, decreased -28.26 % YoY.

arrow icon

What changes have occurred in the market's expectations for Unicycive Therapeutics Inc (UNCY)'s fundamentals?

The market is revising Downward the revenue expectations for Unicycive Therapeutics, Inc. (UNCY) for FY2025, with the revenue forecasts being adjusted by -25% over the past three months. During the same period, the stock price has changed by 49.08%.
arrow icon

How many employees does Unicycive Therapeutics Inc (UNCY). have?

Unicycive Therapeutics Inc (UNCY) has 22 emplpoyees as of December 05 2025.

arrow icon

What is Unicycive Therapeutics Inc (UNCY) market cap?

Today UNCY has the market capitalization of 139.48M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free